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SUMMARY 
Systemic lupus erythematosus (SLE) is a chronic, auto-
immune multi-system disorder. About seventy to nine-
ty percent of all cases of SLE occur in women. Alt-
hough the disease is common in black young women 
residing in Europe and North America, it is reputed to 
be a very rare diagnosis in West Africa. A case of atyp-
ical presentation of SLE in a male in West Africa is 
presented. 
 




Systemic lupus erythematosus (SLE) is a chronic auto-
immune inflammatory disease which can present with 
different combinations of symptoms and also tends to 
mimic other medical conditions, thus making it diffi-
cult to diagnose without delay in most cases. The dis-
ease is more prevalent in the age group 15 to 44 years 
and occurs 90% of the time in females.1The disease is 
said to be rare in West Africa in earlier publications.2,3  
 
The low rate of documented diagnosis in West Africa 
may result from low index of suspicion of the diagnosis 
in patients presenting with atypical features of the dis-
ease and also inadequate laboratory support for the 
diagnosis or a low level of reporting. Studies show that 
SLE tends to occur at an early age in males as com-
pared to females.4 The classic triad of fever, rash and 
joint pains, which was described in earlier literature5 as 
characterizing most cases of SLE does not always oc-
cur in the initial presentation which may further delay 
the diagnosis.  
 
Generally, males tend to have increased frequency of 
discoid lupus, thrombocytopenia, neuropsychiatric and 




A case of SLE with atypical presentation in a 52-year 
old male in West Africa is presented here to highlight 
the need for a high index of suspicion for such cases. 
 
CASE REPORT 
A 52-year old Ghanaian male was admitted to the with 
a two-month history of worsening generalized malaise 
and weight loss. Patient had anorexia, but denied nau-
sea, vomiting, fever, dysuria, cough, diarrhoea or skin 
rash. He complained of hesitancy and straining with 
micturition for about two weeks, and had experienced a 
single episode of gross haematuria about twenty four 
hours prior to presentation to the hospital. He had 
passed very scanty non-bloody urine on the day of ad-
mission. 
 
His past medical history was remarkable only for hy-
pertension diagnosed about 4 years earlier, and for 
which he took 30 mg orally of sustained-release nifedi-
pine daily. He denied any known drug allergies, and 
denied tobacco or alcohol use.  
 
The initial vital signs were normal. There was mild 
pallor with no icterus or lymphadenopathy. There were 
discrete non-tender ulcers on the roof of the mouth and 
on the buccal mucosa.   The cardiovascular and respira-
tory examination findings were unremarkable. The 
abdominal examination showed a tender distended 
bladder, but no hepato-splenomegaly. Patient was con-
scious and alert with normal speech. Muscle power was 
grade 5 in all limbs and Kernig sign was absent.  
 
A Foley catheter was inserted to relieve the acute uri-
nary retention. At about 18 hours after admission, pa-
tient was noted to have rapid onset flaccid paraparesis 
with muscle strength of 1/5 in both lower extremities, 









His laboratory test results are as follows: Total white 
cell count on two occasions was less than 4 x109/L 
(leucopoenia). Haemoglobin was 9.6 then 10.3g/dl 
whilst platelets were normal. Serum folate, B12 and 
CRP were normal. Serum iron and transferrin were low 
and ESR persistently above 100mm/hr. 
 
Blood urea and electrolytes were normal, urinalysis 
showed increased red and white cells, proteinuria and 
white cell casts. Repeat urinalysis was normal.  
Other urinary tests results showed 24-hour urinary pro-
tein of 0.44 g/24hours, no malignant cells on cytology, 
negative PCR for tuberculosis and no bacterial growth 
on culture. 
 
Other blood tests performed, which were normal, in-
clude prostate specific antigen, HIV antibody tests, 
hepatitis B surface antigen, rheumatoid factor, Anti-
Cyclic Citrullinated peptide, C-ANCA, P-ANCA and 
complement 3 and 4. Anti IFA titres, anti-ds-DNA, anti 
Ro and anti-La were all negative. The ANF pattern was 
speckled, Anti -Sm Ab and Anti-RNP68 Ab positive. 
 
A stool occult blood test was negative and serum pro-
tein electrophoresis showed polyclonal gammopathy. A 
chest x-ray and, plain x-ray of lumbar sacral spine were 
normal.  Abdominal/Pelvic ultrasound showed a large 
(10.6 x 7.5 cm2) simple cyst occupying the upper pole 
of the left kidney. The prostate was homogenously 
enlarged with a volume of about 45.1 millilitres. 
 
CT scan of abdomen/pelvis showed enlarged prostate 
with mild bilateral hydronephrosis. The liver, spleen, 
pancreas and adrenal glands appeared normal with no 
ascites or retroperitoneal lymphadenopathy. MRI of 
spine was not done due to unavailability. Cystoscopy 
showed no bladder tumour with normal ureteric orific-
es. Prostate biopsy showed no evidence of malignancy. 
Renal Biopsy was not done. 
 
A diagnosis of systemic lupus erythematosus was made 
after excluding other diagnosis based on the presenting 
features of aphthous ulcers, leucopoenia, and cellular 
casts in the urine, positive antinuclear and anti-Smith 
antibodies. Patient was started on high dose predniso-
lone which was tapered over two months to 10 mg dai-
ly. He was also started concurrently on hydroxychloro-
quine 200mg daily. He participated in daily physio-
therapy for four weeks.  
 
The urinary retention was evaluated by the urology 
service for which he was prescribed tamsulosin and 
dutasteride. The Foley catheter was successfully re-
moved after five weeks. He was also placed on Lis-
inopril and amlodipine for blood pressure control.  
 
After one month on therapy, patient had improved re-
markably. The strength in both lower extremities had 
returned to normal and the aphthous ulcers had disap-
peared. At follow up visit after two months on therapy, 
he had regained his baseline muscle power. All abnor-
mal laboratory parameters had returned to normal. 
 
DISCUSSION 
The classification criteria for systemic lupus erythema-
tosus were updated in 1997. At least four of these elev-
en criteria (in Table 1) are required to classify patients 
as having systemic lupus erythematosus.  
 
Table 1 Criteria for the Classification of Systemic Lu-
pus Erythematosus 
At least 4 of the following are required to classify pa-








Leukopenia (< 4000/µL), lymphopenia (< 1500/µL), 
haemolytic anaemia, or thrombocytopenia (< 
100,000/µL) 
Neurologic disorder 
Positive test for anti-DNA, anti-Smith, or antiphospho-
lipid antibodies 
Antinuclear antibodies in high titres 
 
This patient’s presentation fulfilled five of these eleven 
criteria for a definite diagnosis of systemic lupus ery-
thematosus. Certain aspects of this patient’s presenting 
features are quite atypical for classic SLE at initial 
presentation and could have delayed the diagnosis. 
This discussion will focus on the four atypical aspects 
of his presentation. 
 
Ethnicity, age and gender: Several studies have demon-
strated a marked ethnic/geographic variance in the 
prevalence and severity of SLE around the world. 
There is increased prevalence and severity in people of 
African-American and Afro-Caribbean backgrounds 
resident in North America or Europe, but SLE is rarely 
described in West Africa from where most migrant 
African-American and Afro-Caribbean populations 
originated.3  
 
There are no population-based studies of SLE in West 
Africa, and by 2009, there were about thirty three case 
reports from the West African sub-region.  
 
 




This could be attributable to low level of reporting of 
cases of SLE. On the other hand the study by Molokhia 
et al suggested that the disease is not rare in West Afri-
ca.7  
 
SLE has long been regarded as a disease of young 
women in their twenties and thirties.  Maddock Jr. et al 
noted that men develop SLE less frequently with no 
apparent concentration in any age group.8 Studies have 
shown that young women present classically with c 
fever, joint pains and rash9, whereas men  tend to have 
increased frequency of discoid lupus, thrombocytopae-
nia, neuropsychiatric and renal involvement at the time 
of diagnosis.7   
 
Diagnosis of SLE requires a high index of suspicion. 
The combination of aphthous ulcers, high erythrocyte 
sedimentation rate, and weight loss, anaemia of chronic 
disease, polyclonal gammopathy, leukopenia, pro-
teinuria and white blood cell cast in the absence of ob-
vious infection or malignancy raised suspicion for 
chronic autoimmune disease, especially SLE despite 
the atypical presentation, sex and age. SLE   was sub-
sequently confirmed by increased antinuclear antibody 
and anti-Smith antibody. 
 
Complements C3 and C4 are acute phase reactants that 
may manifest increased serum levels in serum during 
inflammatory flares of SLE. On the other hand, in-
creased consumption during flares may result in hypo-
complementaemia. Harvey et al noted in their review 
of SLE that low serum complement C4 is very infre-
quent in over the age forty years.10 The patients presen-
tation was thus atypical. 
 
According to the American College of Rheumatology, 
a total of 19 neuropsychiatric syndromes that can occur 
in the course of SLE have been described and defined.  
 
The most common syndromes are cognitive disorders, 
mood disorders, headaches, seizures and cerebrovascu-
lar disease. Myelopathy is one of the less common neu-
ropsychiatric manifestations of systemic lupus erythe-
matosus with a reported prevalence of about 1-3%.11  
 
Transverse myelitis commonly presents as a late mani-
festation of systemic lupus erythematosus, but there 
have been reports of transverse myelitis presenting at 
disease onset with high association with antiphospho-
lipid antibodies and with good response to treatment.12  
 
This patient’s paraparesis which was presumed to be 
secondary to myelopathy could not be evaluated further 
with antiphospholipid antibody tests, MRI, myelogram 
or nerve conduction velocities due to limited resources.  
 
Nonetheless, this patient made a rapid and complete 
recovery of motor function in both lower extremities 
following initiation of steroids, hydroxychloroquine 
and physiotherapy. 
 
Presence of anti-Smith and Anti-RNP antibodies: Anti-
bodies to double-stranded DNA are often measured in 
SLE and are useful in the diagnosis of the condition, 
but the levels tend to fluctuate and they may be absent 
at times as was observed in this patient. Antibodies 
directed against small nuclear riboprotein include anti-
Smith antibody and antiribonuclear protein (anti-RNP) 
antibodies.  
 
They bind to related but distinct antigens. Anti-Smith 
antibodies can be used for confirming the diagnosis of 
SLE. They have a low a sensitivity of 24% to 30% but 
a high specificity of 96% to 98%. Anti-Smith antibod-
ies are known to be more prevalent in black patients.13 
Anti-RNP antibodies coexist with anti-Smith antibod-
ies in many patients with systemic lupus erythemato-
sus.14 It is therefore important for clinicians in West 
Africa to test for the anti-Smith and anti-RNP antibod-
ies in addition to anti ds-DNA antibodies in patients 
suspected to have SLE.  
 
CONCLUSION 
Systemic lupus erythematosus is uncommon in males 
and atypical presentation may make the diagnosis ex-
tremely difficult. This case report seeks to draw medi-
cal practitioners’ attention in the West African sub re-
gion to the probability of systemic lupus erythematosus 
in males as well as the possibility of presentation with 
very atypical features. Laboratory tests to aid diagnosis 
may be unaffordable and clinicians need to have a high 
index of suspicion to be able to recognise the disease in 
patients who present atypically. 
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